All publications

Export 159 results:
Author Title Type [ Year(Asc)]
2011
Bansi L, Smith C, Phillips AN, Kirk S., Geretti AM, Johnson M, Mackie N, Post FA, Gazzard B, Dunn DT et al..  2011.  The impact of HIV drug resistance testing on changes to treatment. AIDS. 25:603-10.
Dunn DT, Coughlin K., Cane P A.  2011.  Genotypic resistance testing in routine clinical care. Curr Opin HIV AIDS. 6:251-7.
Prosperi M.C, Mackie N, Di Giambenedetto S., Zazzi M, Camacho R., Fanti I., Torti C., Sonnerborg A., Kaiser R., Codoner F.M et al..  2011.  Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother. 66:1886-96.
Cozzi-Lepri A, Prosperi M.C, Kjaer J., Dunn DT, Paredes R, Sabin CA, Lundgren J, Phillips AN, Pillay D.  2011.  Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score PLoS One. 6:e25665.
Ambrose JC, Foster GM, Fearnhill E, Leigh Brown A, Porter K, Mackie N, Fidler S, Geretti AM, On behalf of the UK Register of HIV Seroconverters and the UK HIV Drug Resistance Database.  2011.  The contribution of recent infections to HIV-1 transmission clusters in the UK. 18th International HIV Dynamics and Evolution Conference, 1-4 May 2011.
Foster GM, Ambrose JC, Hue S, Conibear T, Fearnhill E, Abecasis AB, Leigh Brown A, Geretti AM, UK HIV Drug Resistance Database.  2011.  Mapping the circulation of HIV-1 recombinants among MSM. 18th Conference on Retroviruses and Opportunistic Infections, 27 Feb - 2 Mar 2011.
Hue S, Fearnhill E, Dunn DT, Delpech V, Pillay D, Leigh Brown A, UK HIV Drug Resistance Database.  2011.  Phylogeographic and Risk Group Characteristics of HIV Subtype A Transmission in the UK. 18th Conference on Retroviruses and Opportunistic Infections, 27 Feb - 2 Mar 2011.
Hue S, Fearnhill E, Dunn DT, Delpech V, Pillay D, Leigh Brown A, UK HIV Drug Resistance Database.  2011.  Phylogeographic and risk group characteristics of HIV-1 Subtype A transmission in the UK. 18th International HIV Dynamics and Evolution Conference, 1-4 May 2011.
Klein M, Odueyungbo A, Scherrer A, Ledergerber B, Fearnhill E, Sabin CA, Hogg R, Cozzi-Lepri A, Gill J, Tan D et al..  2011.  Impact of Viral Subtype on Immunologic and Clinical Disease Progression in Antiretroviral-naïve HIV-infected Adults. 18th Conference on Retroviruses and Opportunistic Infections, 27 Feb - 2 Mar 2011.
Leigh Brown A, Lycett S, Weinert L, Hughes GJ, Fearnhill E, Dunn DT, UK Collaborative Group on HIV Drug Resistance.  2011.  HIV transmission dynamics. Keystone Conference on HIV Evolution, Genomics and Pathogenesis, 26-31March 2011.
Mackie N, Garvey L, Geretti AM, Harrison LJ, Tilston P, Phillips AN, Sabin CA, Dunn DT.  2011.  Predicting NNRTI resistance - do polymorphisms matter? 18th Conference on Retroviruses and Opportunistic Infections, 27 Feb - 2 Mar 2011.
Santoro MM, Silberstein FC, Forbici F., Bansi L, Dunn DT, Fearnhill E, Boumis E, Narciso P, Antinori AM, Palamara G et al..  2011.  Different drug-resistance development in HIV-1 infected patients failing a first-line antiretroviral therapy containing NNRTIs. IAS, 17-20 July 2011.
Barber TJ, Harrison LJ, Asboe D, Williams I, Bansi L, Pillay D, Dunn DT.  2011.  Prevalence and predictors of protease inhibitor (PI) mutations in HIV-infected UK adults treated with ritonavir-boosted lopinavir as their first PI. 17th Annual Conference of the British HIV Association, 6-8 April 2011.
2010
Fox J, Castro H, Kaye S, McClure M, Weber JN, Fidler S.  2010.  Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK. AIDS. 24:2397-401.
Mackie N, Phillips AN, Kaye S, Booth C, Geretti AM.  2010.  Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis. 201:1303-7.
UK Collaborative Group on HIV Drug Resistance, UK Collaborative HIV Cohort Study(UK CHIC).  2010.  Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin Infect Dis. 50:1275-85.
Harrison LJ, Castro H, Cane P A, Pillay D, Booth C, Phillips AN, Geretti AM, Dunn DT.  2010.  The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS. 24:1917-22.
Dunn DT, von Wyl V., Price H., Asboe D.  2010.  The impact of the 0-0 cell on measures of amino acid covariation. AIDS. 24:159-60.
Bansi L, Geretti AM, Dunn DT, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, Porter K, Phillips AN et al..  2010.  Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). J Acquir Immune Defic Syndr. 53:633-9.
Chilton DN, Castro H, Lattimore S, Harrison LJ, Fearnhill E, Delpech V, Rice B., Pillay D, Dunn DT.  2010.  HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Antivir Ther. 15:985-91.